PDE5 Inhibitor Powder Formulations for Direct Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oral administration of PDE5 inhibitors results in poor and variable bioavailability and extensive liver metabolism, leading to systemic side effects and limited effectiveness for conditions like pulmonary hypertension and cystic fibrosis.
Innovation Solution
Development of a powder pharmaceutical composition containing at least 2% PDE5 inhibitor with a pharmaceutically acceptable carrier, aerosolized using an inhaler with a movable actuator to deliver the composition directly to the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of PDE5 inhibitors is used, then the drug can be delivered systemically, but bioavailability is poor and variable with extensive liver metabolism causing systemic side effects
Solution Approach 1:
The patent extracts the drug delivery from the oral route and redirects it to the pulmonary route. By formulating PDE5 inhibitors as inhalable powders or aerosols, the drug is delivered directly to the lungs, bypassing the liver's first-pass metabolism and reducing systemic circulation of the drug, thereby minimizing systemic side effects while improving bioavailability at the target site.
Solution Approach 2:
The patent introduces the lung as an intermediary delivery site between oral administration and systemic circulation. By targeting the lungs directly via inhalation, the drug achieves local high concentration at the site of action (pulmonary vasculature) while avoiding extensive hepatic metabolism and reducing the amount of drug that reaches systemic circulation, thus improving reliability while reducing harmful effects.
2Reliability
If oral doses are increased to improve effectiveness, then more drug reaches the target, but the incidence of systemic side effects increases
Solution Approach 1:
The patent applies local quality by creating high drug concentration locally in the lungs through inhalation delivery. The pulmonary administration route ensures that the highest drug concentration is achieved at the target site (pulmonary vasculature and lung tissue) without proportionally increasing systemic exposure. This allows effective treatment of pulmonary conditions while minimizing systemic side effects, as the drug acts primarily where it is needed rather than circulating systemically at high levels.
3Reliability
If pulmonary delivery is implemented, then direct lung tissue delivery is achieved, but device complexity increases with inhaler requirements
Solution Approach 1:
The patent employs disposable single-use inhaler devices or pre-filled inhalation cartridges containing the PDE5 inhibitor powder formulation. These disposable units eliminate the need for complex cleaning, sterilization, and maintenance of reusable devices. Each disposable unit is pre-loaded with the precise dose and can be discarded after a single use, significantly reducing device complexity while ensuring reliable pulmonary drug delivery. This approach also maintains dosing accuracy and avoids cross-contamination issues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances drug delivery to the lung tissue, overcoming bioavailability issues and reducing systemic side effects, making it effective for treating conditions like pulmonary hypertension and cystic fibrosis.
Implementation Method 1
a method of aerosolizing a powder pharmaceutical composition
Data Source
AI summary
Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.